###### Strengths and limitations of this study

-   This novel study will capture perspectives on the barriers and enablers of optimal PRO practice from a comprehensive range of stakeholders with experience of patient-reported outcome (PRO) data collection and reporting.

-   The semistructured interview format ensures a replicable process while allowing sufficient freedom to explore new and emerging concepts.

-   The recruitment strategy involves seeking participants through networks occupied by Evaluation of Patient-Reported Outcome (PRO) Protocol Content and Reporting in UK Cancer Clinical Trials Senior Management Group members. However, any limitation to sample representativeness and diversity will be mediated through the use of other recruitment avenues including the authorship lists of the protocols/publications included in phase I.

-   Study is at risk of self-selection and social desirability bias. Participants are likely to take part if they have a pre-existing interest in PROs specifically and when recounting their experiences and insights are likely to wish to portray themselves in a positive manner due to the nature of this study.

Introduction {#s1}
============

Patient-reported outcomes (PROs) are increasingly included within cancer clinical trials to provide the patient perspective on the physical, functional and psychological consequences of treatment and the degree and impact of disease symptoms.[@R1] The number of randomised controlled clinical trials including PROs is now substantial across all cancer disease sites, and these often include PROs as secondary endpoints.[@R2] PROs are typically collected using multidimensional questionnaires in electronic or paper format and are completed by patients while they are participating in clinical trials. The results provide information about the symptoms or quality of life effects of a particular therapy and may inform future treatment choices and help physicians and patients decide the most suitable treatment and care for the individual. Rigorous study design and standardised data collection methods are required to collect the highest quality PRO data and adhering to good practice minimises errors, measurement variability, missing data and systematic bias, upholding trial validity.[@R3]

The use of PROs in cancer clinical trials has been exhorted by major international health policy and regulatory authorities as well as patients with cancer.[@R4] PRO trial results inform clinical decision making; health technology assessment; health economic evaluations; labelling claims; healthcare policy; and commissioning[@R7] when rigorously captured. PRO data can enhance clinician--patient communication relating to treatment options and contribute to complex healthcare decision making[@R11] by providing information on relative benefits and side effects of new drugs or treatment options.[@R13] Using this information, patient--clinician consultations may result in more informed choices, positive results and favourable experiences of care.[@R18] As such, guidance included in trial protocols must ensure appropriate PRO data collection and management,[@R20] and results must be fully reported in resulting publications so that PRO information is readily publicly accessible to patients and integrated into clinical practice and policy.[@R21]

Recent international evidence,[@R22] however, suggests PRO information is often omitted from protocols, leading to impaired data collection. Such research also suggests that PRO results are poorly reported in trial publications, or may not be reported at all.[@R22] Our previous review of 75 National Institute for Health Research Health Technology Assessment trials[@R23] found that relevant PRO information is commonly omitted from trial protocols, even where a PRO is the primary outcome. As a result, PRO data may not be used effectively to inform patient--clinician decision making at the point of diagnosis and beyond. This represents a waste of limited healthcare and research resources, devalues the contribution of trial participants providing PRO data and has serious ethical implications.

While there has been some qualitative research investigating PRO administration in trials,[@R24] there has been little qualitative work investigating the factors affecting PRO trial design, protocol development and reporting.

The Evaluation of Patient-Reported Outcome (PRO) Protocol Content and Reporting in UK Cancer Clinical Trials (EPiC) study is a mixed method study investigating PRO protocol content and reporting in UK cancer clinical trials aiming to identify factors that enable and inhibit good practice. The research will take place over three stages; the methods pertaining to phase I are presented in detail elsewhere.[@R27]

This paper provides a summary of the phase II qualitative component, in which semistructured interviews will be conducted to explore the potential barriers and enablers relating to optimal PRO protocol content, implementation and reporting with cancer trialists, research nurses (RNs), consumer representatives, international experts, journal editors and funders. Through the inclusion of individuals from each of these groups, the collection and reporting of PRO data can be considered by the individuals involved at every phase of the research process---including study conception and design and patients' experiences of providing PRO data as trial participants---until the point at which results are communicated. Phase III of the study will incorporate findings and examples of best practice from both phases I and II into our publicly accessible, web-based training resource ([www.birmingham.ac.uk/prolearn](www.birmingham.ac.uk/prolearn)).

Aims {#s2}
====

Semistructured telephone and face-to-face interviews will be conducted (AR) to explore the perspectives and experience of key stakeholders in relation to:the potential barriers and enablers to optimal PRO protocol content, implementation and reportingthe PRO-specific training needs of each stakeholder groupthe optimal methods of implementing such training and ensuring uptake of both the forthcoming SPIRIT-PRO[@R28] and published CONSORT-PRO[@R29] guidelines.

Participants and setting {#s3}
========================

The primary inclusion criteria are that participants must have experience of designing or reviewing clinical trials including PROs within a professional capacity or completion of PROs through participation in a trial. Interviewees will be sampled from four groups: (1) trial chief investigators, trial management group members, statisticians and RNs with experience of involvement in a cancer trial including primary or secondary PRO; (2) National Cancer Research Institute (NCRI) Consumer Liaison Group members with experience of involvement in the design of trials with PRO endpoints; (3) international experts in PRO oncology trial design, including members of multicountry cancer and quality of life research organisations, national regulatory bodies, advisory bodies and global corporations; and (4) journal editors and key representatives from funding bodies. Based on the experience of the research team, it is anticipated that recruitment of approximately 8--12 individuals from each group will be required to reach data saturation. Thus, up to 48 participants may be required. Individuals will be purposively selected based on having occupied a role within trials in management, data collection, as a patient partner or a participant. The categorisation of participants into the above four groups will allow the research team to attain maximum variation with regards to experience and role. Recruitment will continue for each distinct group until data saturation is achieved.

Group 1 will be identified from: (1) the authorship lists of the trial protocols/publications included in phase I or (2) NCRI Clinical Studies Groups and Consumer Liaison Group and the UK Clinical Research Collaboration Registered UK Clinical Trial Unit (UKCRC-UKCTU) Network, facilitated by an EPiC study management member who is also the UKCRC-UKCTU network director. Trials from phase I will be purposively selected to ensure representation across the following criteria: clinical area, SPIRIT-PRO and CONSORT-PRO checklist score[@R23] and funding source. Group 2 participants will be identified via the NCRI Consumer Liaison Group, facilitated by an EPiC study management member who is also the NCRI Psychosocial Oncology and Survivorship Clinical Studies Group chair. Group 3 will be identified using the personal contacts of the study management group, in particular via an EPiC study senior management group member who is also director of the Centre for Patient-Reported Outcomes Research at the University of Birmingham. Group 4 will be identified using publicly available information via the appropriate journal/funder website.

Data collection {#s4}
===============

Potential participants will be approached via email (either directly where contact details are in the public domain or via the centre from which they were identified where appropriate) and provided with a brief outline of the project aims, the consent form and information sheet and details of how to register interest. Individuals interested in taking part will be contacted by the research fellow (AR) and will be given an opportunity to ask further questions before deciding whether to take part in the study. An interview date will be set for those wishing to participate. Participants will be first offered a telephone interview. In cases where the individual wishes to participate in an interview but would prefer to do so in person rather than via telephone, this will be arranged if feasible.

Participants will be sent a consent form to complete. The researcher will request that the consent form is returned prior to the interview. In cases where a consent form has not been received by the researcher in advance of the interview, verbal consent will be audio-recorded and taken via a standardised script immediately prior to the interview. If a participant would prefer their verbal consent is not audio-recorded, verbal consent will still be taken prior to interview but on the understanding that a consent form will be sent by the researcher to the participant immediately after the interview to be signed and returned.

The interviews will last for approximately 1 hour. Participants will be interviewed using a predefined topic guide (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}) with sufficient scope to explore novel themes where appropriate and will be audio-recorded. Interview recordings will be professionally transcribed verbatim. All participants will remain anonymous, and all data will be treated as confidential.
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Study dates: March 2016--September 2018.

Analysis {#s5}
========

Interview transcripts will be analysed using directed thematic analysis (AR) whereby findings from previous qualitative and review work[@R24] and the analysis of included protocols and publications from phase I will be used in addition to developing an initial coding framework.[@R31] Additional codes will be developed as the analysis progresses and the framework will be modified accordingly.[@R31] Formal triangulation of coding will be employed to enhance the credibility of the analysis. This will be undertaken at regular intervals during analysis when a subsample of transcripts will be coded by an additional researcher (DK/MC), and differences will be discussed to ensure intercoder agreement.

The findings from this phase, in combination with the phase I findings, will be used in phase III to highlight examples of best practice in PRO protocol design and reporting and inform the development of an online PRO training resource.

Dissemination {#s6}
=============

The results of this study will be disseminated via presentations at local, national and international conferences, peer-reviewed journals and through social media including the Centre for Patient Reported Outcomes Research's Twitter account and the University of Birmingham departmental website (<http://www.birmingham.ac.uk/cpror>), as well as the NCRI (including the consumer forum), Macmillan Cancer Support and via international cancer trial groups. Participants will be anonymised, and all data collected will be treated as confidential. Only anonymised, non-identifiable characteristics and quotes will be used in any arising publications/reports.

Protocol and registration {#s7}
=========================

This study protocol for the wider programme of work is registered on PROSPERO (CRD42016036533). Registration details are available at <http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016036533>.

Discussion {#s8}
==========

Existing evidence and pilot data collected to demonstrate the feasibility of our approach suggests there may be substantial variation in PRO protocol content and reporting in UK cancer clinical trials. The qualitative component of the EPiC study will explore and explain the contributing factors with stakeholders and establish how clinical trial practice may be improved and supported through training and other resources. This work could benefit several groups including researchers and those involved in research dissemination and service delivery. Appropriate collection, analysis, rationale and reporting of PROs may result in comprehensive data on which treatment decisions may be based, benefiting patients, but would also promote more effective use of public and charitable funds.

This work represents the PRO component within a far wider effort to promote effective, robust and transparent practice within clinical trials. Initiatives focusing on improving practice relating to various aspects of clinical trials[@R32] have been lauded and are changing practice through their use.[@R35] The inconsistent use of PROs in cancer clinical trials is well documented; however, the findings from this programme of research have the potential to address these shortcomings through the development of tailored PRO training and guidance for key stakeholders.
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